Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.

Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, Kaneko S, Garcia BA, Hamilton AD, Reinberg D.

Mol Cell. 2018 May 3;70(3):422-434.e6. doi: 10.1016/j.molcel.2018.03.020. Epub 2018 Apr 19.

2.

Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.

Lee CH, Holder M, Grau D, Saldaña-Meyer R, Yu JR, Ganai RA, Zhang J, Wang M, LeRoy G, Dobenecker MW, Reinberg D, Armache KJ.

Mol Cell. 2018 May 3;70(3):435-448.e5. doi: 10.1016/j.molcel.2018.03.019. Epub 2018 Apr 19.

3.

Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.

Imagawa E, Higashimoto K, Sakai Y, Numakura C, Okamoto N, Matsunaga S, Ryo A, Sato Y, Sanefuji M, Ihara K, Takada Y, Nishimura G, Saitsu H, Mizuguchi T, Miyatake S, Nakashima M, Miyake N, Soejima H, Matsumoto N.

Hum Mutat. 2017 Jun;38(6):637-648. doi: 10.1002/humu.23200. Epub 2017 Mar 15.

PMID:
28229514
4.

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).

Yang CY, Wang S.

J Med Chem. 2017 Mar 23;60(6):2212-2214. doi: 10.1021/acs.jmedchem.7b00287. Epub 2017 Mar 3.

PMID:
28256832
5.

Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.

Cohen AS, Yap DB, Lewis ME, Chijiwa C, Ramos-Arroyo MA, Tkachenko N, Milano V, Fradin M, McKinnon ML, Townsend KN, Xu J, Van Allen MI, Ross CJ, Dobyns WB, Weaver DD, Gibson WT.

Hum Mutat. 2016 Mar;37(3):301-7. doi: 10.1002/humu.22946. Epub 2016 Jan 12.

6.

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Wassef M, Luscan A, Aflaki S, Zielinski D, Jansen PWTC, Baymaz HI, Battistella A, Kersouani C, Servant N, Wallace MR, Romero P, Kosmider O, Just PA, Hivelin M, Jacques S, Vincent-Salomon A, Vermeulen M, Vidaud M, Pasmant E, Margueron R.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.

7.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

Qi W, Zhao K, Gu J, Huang Y, Wang Y, Zhang H, Zhang M, Zhang J, Yu Z, Li L, Teng L, Chuai S, Zhang C, Zhao M, Chan H, Chen Z, Fang D, Fei Q, Feng L, Feng L, Gao Y, Ge H, Ge X, Li G, Lingel A, Lin Y, Liu Y, Luo F, Shi M, Wang L, Wang Z, Yu Y, Zeng J, Zeng C, Zhang L, Zhang Q, Zhou S, Oyang C, Atadja P, Li E.

Nat Chem Biol. 2017 Apr;13(4):381-388. doi: 10.1038/nchembio.2304. Epub 2017 Jan 30.

PMID:
28135235
8.

Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.

Sanulli S, Justin N, Teissandier A, Ancelin K, Portoso M, Caron M, Michaud A, Lombard B, da Rocha ST, Offer J, Loew D, Servant N, Wassef M, Burlina F, Gamblin SJ, Heard E, Margueron R.

Mol Cell. 2015 Mar 5;57(5):769-783. doi: 10.1016/j.molcel.2014.12.020. Epub 2015 Jan 22.

9.

EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.

Mu W, Starmer J, Yee D, Magnuson T.

Epigenetics Chromatin. 2018 Dec 6;11(1):71. doi: 10.1186/s13072-018-0242-9.

10.

Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.

Kong X, Chen L, Jiao L, Jiang X, Lian F, Lu J, Zhu K, Du D, Liu J, Ding H, Zhang N, Shen J, Zheng M, Chen K, Liu X, Jiang H, Luo C.

J Med Chem. 2014 Nov 26;57(22):9512-21. doi: 10.1021/jm501230c. Epub 2014 Nov 12.

PMID:
25369470
11.

Live-cell imaging reveals the dynamics of PRC2 and recruitment to chromatin by SUZ12-associated subunits.

Youmans DT, Schmidt JC, Cech TR.

Genes Dev. 2018 Jun 1;32(11-12):794-805. doi: 10.1101/gad.311936.118. Epub 2018 Jun 11.

12.

Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.

Lavarone E, Barbieri CM, Pasini D.

Nat Commun. 2019 Apr 11;10(1):1679. doi: 10.1038/s41467-019-09624-w.

13.

Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.

Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, Myint SS, Loh JL, Ong P, Sam XX, Huang D, Lim T, Tan PH, Nagarajan S, Cheng CW, Ho H, Ng LG, Yuen J, Lin PH, Chuang CK, Chang YH, Weng WH, Rozen SG, Tan P, Creasy CL, Pang ST, McCabe MT, Poon SL, Teh BT.

Sci Transl Med. 2017 Feb 22;9(378). pii: eaai8312. doi: 10.1126/scitranslmed.aai8312.

PMID:
28228601
14.

The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.

Streubel G, Watson A, Jammula SG, Scelfo A, Fitzpatrick DJ, Oliviero G, McCole R, Conway E, Glancy E, Negri GL, Dillon E, Wynne K, Pasini D, Krogan NJ, Bracken AP, Cagney G.

Mol Cell. 2018 Apr 19;70(2):371-379.e5. doi: 10.1016/j.molcel.2018.02.027. Epub 2018 Mar 29.

15.

Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).

Xu C, Bian C, Yang W, Galka M, Ouyang H, Chen C, Qiu W, Liu H, Jones AE, MacKenzie F, Pan P, Li SS, Wang H, Min J.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19266-71. doi: 10.1073/pnas.1008937107. Epub 2010 Oct 25.

16.

Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.

Gall Trošelj K, Novak Kujundzic R, Ugarkovic D.

Clin Epigenetics. 2016 May 27;8:55. doi: 10.1186/s13148-016-0226-1. eCollection 2016. Review.

17.

A model for transmission of the H3K27me3 epigenetic mark.

Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K.

Nat Cell Biol. 2008 Nov;10(11):1291-300. doi: 10.1038/ncb1787. Epub 2008 Oct 19. Erratum in: Nat Cell Biol. 2008 Dec;10(12):1484.

PMID:
18931660
18.

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.

Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3735-44. doi: 10.1073/pnas.1602079113. Epub 2016 Jun 14.

19.

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.

Brooun A, Gajiwala KS, Deng YL, Liu W, Bolaños B, Bingham P, He YA, Diehl W, Grable N, Kung PP, Sutton S, Maegley KA, Yu X, Stewart AE.

Nat Commun. 2016 Apr 28;7:11384. doi: 10.1038/ncomms11384.

20.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

Supplemental Content

Support Center